Clinic Diagnostic Imaging Health Science Radiation Oncology 
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
Expert insights. Personalized for you.
122 
Let's personalize your content